Premature Menopause

Definition & Etiology - Early Ovarian Fade

• Definition: Premature Ovarian Insufficiency (POI) is cessation of ovarian function before age 40.
  • Key features: Amenorrhea (≥4 mo), ↑FSH >40 mIU/mL (x2, ≥1 mo apart), ↓Estradiol.
• Etiology:
  • Idiopathic: Most common (~75-90%).
  • Genetic: Turner syndrome (45,X0), Fragile X premutation (FMR1), galactosemia, FOXL2 (BPES).
  • Autoimmune: Isolated oophoritis, Polyglandular Autoimmune Syndrome (e.g., Addison's, thyroiditis).
  • Iatrogenic: Chemotherapy (alkylating), pelvic radiotherapy, ovarian surgery.
  • Infections (Rare): Mumps oophoritis.
  • Environmental: Smoking.

⭐ Fragile X premutation (FMR1 gene) carriers have a ~20% risk of developing POI.

Clinical Features & Diagnosis - Spotting POI Signs

• Clinical Presentation (< 40 yrs):
  • Menstrual: Oligo/amenorrhea (≥ 4 months).
  • Vasomotor: Hot flushes, night sweats.
  • Urogenital: Vaginal dryness, dyspareunia, recurrent UTIs.
  • Psychological: Mood swings, irritability, sleep issues.
  • Subfertility or infertility.
• Diagnostic Confirmation:
  • ↑ FSH: > 25-40 IU/L (2 occasions, 4-6 wks apart).
  • ↓ Estradiol (E2): < 50 pg/mL (often < 20 pg/mL).
  • Exclude other causes (pregnancy, thyroid, prolactin).
  • Further tests: Karyotype (<30y), FMR1, autoimmune screen, AMH, AFC.

⭐ Key diagnostic criteria: Amenorrhea (≥ 4 months) before age 40 AND two FSH levels > 25-40 IU/L (taken 4-6 weeks apart).

Investigations - Unmasking POI Clues

• Hormonal Profile (Key):
  • ↑ Serum FSH: >40 IU/L (2 samples, >4 wks apart) - Diagnostic
  • ↓ Serum Estradiol (E2): Consistent with ovarian failure
  • ↓ AMH (Anti-Müllerian Hormone): Low ovarian reserve marker
• Genetic Evaluation:
  • Karyotype: Essential to exclude Turner syndrome (45,X), other X-chr anomalies
  • FMR1 premutation: Test for Fragile X carrier status
• Autoimmune Screen:
  • Targeted: Thyroid (anti-TPO), adrenal antibodies if clinical suspicion
• Imaging:
  • Pelvic Ultrasound (TVS): Shows small ovaries, ↓ antral follicle count (AFC)

⭐ Two FSH levels >40 IU/L, measured at least 1 month apart, are diagnostic for POI in women <40 years.

Management & Complications - Tackling POI Challenges

• Core Goals: Symptom relief, prevent long-term risks (osteoporosis, CVD), address fertility.
• Hormone Replacement Therapy (HRT):
  • Physiological doses until average age of natural menopause (approx. 51 yrs).
  • Regimens: Combined Estrogen + Progestin (if uterus present); Estrogen-only (post-hysterectomy).
  • Transdermal route often preferred (lower VTE risk).
  • Benefits: Alleviates vasomotor symptoms, urogenital atrophy; preserves bone mineral density; potential cardioprotection.
• Lifestyle & Nutrition:
  • Calcium: 1200-1500 mg/day.
  • Vitamin D: 800-1000 IU/day.
  • Regular weight-bearing exercise.
  • Smoking cessation; psychological support.
• Fertility Considerations:
  • Essential counseling: Oocyte donation (highest success rates), adoption.
  • Spontaneous pregnancy occurs in <5-10% of women.
• Long-term Complications (if untreated/undertreated):
  • Osteoporosis and fragility fractures.
  • Increased risk of Cardiovascular Disease (CVD).
  • Urogenital atrophy (dyspareunia, recurrent UTIs).
  • Mood disorders (depression, anxiety); potential adverse cognitive effects.

⭐ HRT in POI is crucial not only for symptom management but also for long-term health, significantly reducing risks of osteoporosis and cardiovascular disease.

High-Yield Points - ⚡ Biggest Takeaways

• Premature Ovarian Insufficiency (POI): Menopause before age 40 with amenorrhea, hypoestrogenism.
• Diagnosis: ↑ FSH (>25-40 IU/L) & ↓ estradiol in women <40 years.
• Causes: Idiopathic (most common); genetic (Turner, FMR1), autoimmune, iatrogenic.
• Risks: ↑ osteoporosis, cardiovascular disease (CVD), infertility, mood disorders.
• Management: HRT until average menopausal age (~51 years) is crucial for health.
• Fertility counseling (e.g., oocyte donation) and psychological support are key.
• Investigations: Karyotype (<30y), FMR1 testing for premutation carriers.